NFKB1 and cancer: It has been reported that compounds 1 and 2 can suppress LPS-induced inflammatory responses through their inhibition of the NF-κB pathway, as well as inhibiting the growth of certain cancer cells, including HT29 (human colon adenocarcinoma cells), HL60 (human leukemia cells) and Hep 3B (human hepatocellular carcinoma cells) cells [13, 19, 20].